Efficacy and patient-reported outcomes of a new mometasone cream treating atopic eczema

Skin Pharmacology and Physiology

Volumn 25, Issue 6, 2012, Pages 305-312

  Ruzicka, Thomas ^a   Willers, Christoph ^b   Wigger Alberti, Walter ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Almirall Hermal GmbH   (Germany)

^c Bioskin GmbH   (Germany)

Author keywords

Atopic eczema; Corneometry; Cream; Efficacy; Mometasone furoate; Patient acceptance; Quality of life

Indexed keywords

MOMETASONE FUROATE; MONOVO; UNCLASSIFIED DRUG;

APPLICATION SITE EXCORIATION; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULARY; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FEMALE; HUMAN; LICHENOID ERUPTION; MALE; PAPULE; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; SKIN CRUST; SKIN DISEASE; SKIN EDEMA; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PREGNADIENEDIOLS; QUALITY OF LIFE; SELF REPORT; SKIN CREAM; TREATMENT OUTCOME;

EID: 84865579047     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000341809     Document Type: Article

References (13)

1. Darsow U, Lubbe J, Taieb A, Seidenari S, Wollenberg A, Calza AM, et al: Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005; 19: 286-295. (Pubitemid 40691704)
2. Peterson JD, Chan LS: A comprehensive management guide for atopic dermatitis: Topical therapy. Dermatol Nurs 2006; 18: 531- 542.
3. Luger TA: Topische Dermatotherapie mit Glukokortikoiden; in Korting HC, Callies R, Reusch M, Schlaeger M. Sterry W (eds): Dermatologische Qualitätssicherung. Leitlinien und Empfehlungen. Berlin, ABW Wissenschaftsverlag, 2009, pp 943-951.
4. Prakash A, Benfield P: Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 1998; 55: 145-163. (Pubitemid 28035129)
5. Kulhalli P, Chevli T, Karnik R, Sheth M, Mulgaonkar N: Comparative potency of formulations of mometasone furoate in terms of inhibition of 'PIRHR' in the forearm skin of normal human subjects measured with laser Doppler velocimetry. Indian J Dermatol Venereol Leprol 2005; 71: 170-174. (Pubitemid 40898200)
6. Kerscher MJ, Hart H, Korting HC, Stalleicken D: In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 1995; 33: 187-189.
7. Kirkland R, Pearce DJ, Balkrishnan R, Feldman SR: Critical factors determining the potency of topical corticosteroids. J Dermatol Treat 2006; 17: 133-135. (Pubitemid 44147828)
8. Koivukangas V, Karvonen J, Risteli J, Oikarinen A: Topical mometasone furoate and betamethasone-17-valerate decrease collagen synthesis to a similar extent in human skin in vivo. Br J Dermatol 1995; 132: 66-68.
9. Hoffmann K, Auer T, Stücker M, Hofmann A, Altmeyer P: Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol 1998; 10: 137-142. (Pubitemid 28137574)
10. Faergemann J, Christensen O, Sjövall P, Johnssson A, Hersle K, Nordin P, Edmar B, Svensson A: An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2000; 14: 393-396. (Pubitemid 32898894)
11. Brazzini B, Pimpinelli N: New and established topical corticosteroids in dermatology. Am J Clin Dermatol 2002; 3: 47-58.
12. Korting HC, Maslen K, Gross G, Willers C: Vergleich der Wirksamkeit verschiedener topischer Glukokortikoidcremes und -salben im Vasokonstriktionstest: Überlegenheit von Hydrocortisonbutyrat gegenüber Hydrocortison. J Dtsch Dermatol Ges 2005; 3: 348-353. (Pubitemid 40754641)
13. Korting HC, Schöllmann C, Willers C, Wigger-Alberti W: Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%. Skin Pharmacol Physiol 2012; 25: 133-141.